At Creative Peptides, we deliver enterprise-grade Peptides–Carrier Protein Conjugation solutions to accelerate anti-peptide antibody development, immunoassay reagent production, and epitope-focused vaccine research. We conjugate synthetic peptides (linear, cyclic, long, and PTM peptides) to validated carrier proteins such as KLH, BSA, OVA, HSA, and CRM197 using controlled chemistries, optimized linkers, and fit-for-purpose purification. With robust QC, defined peptide loading targets, and scalable manufacturing options, our peptide immunogen and assay antigen conjugates are designed for reproducibility across discovery, preclinical development, and multi-site enterprise workflows.
Peptides are often poor immunogens on their own and may not generate high-titer, high-affinity antibodies—especially for short epitopes, hydrophobic regions, or post-translational modification (PTM) targets. In addition, inconsistent peptide loading and insufficient QC can introduce variability that delays antibody campaigns and assay transfer.
Standardized peptides–carrier protein conjugation workflow designed to support reproducible immunogen production and assay-ready conjugates for enterprise antibody and diagnostic programs.Peptides–Carrier Protein Conjugation addresses these challenges by:
We provide an end-to-end peptide carrier protein conjugation service engineered for enterprise customers who require reproducible peptide immunogens and assay-ready peptide–protein conjugates. Our offering is structured as a modular, QC-driven workflow—from epitope and conjugation strategy design through peptide synthesis, carrier selection, controlled coupling, purification, and documentation. We support standard and complex peptide formats (including phospho-peptides and other PTM peptides) and provide dual-carrier strategies (e.g., KLH for immunization plus BSA/OVA for ELISA screening) to improve specificity and reduce anti-carrier background. Each delivery is tailored for downstream success in antibody production, immunoassay development, and vaccine R&D.
We help enterprise R&D teams convert peptide sequences into high-performing immunogens and screening antigens with a design-first approach:
Deliverables include a technical plan with recommended peptide format, carrier(s), coupling route, target loading range, and QC scope—optimized for speed and reproducibility.
We manufacture high-quality peptides using solid-phase peptide synthesis (SPPS) with defined handles for controlled conjugation and consistent performance.
Peptide design and synthesis are aligned to conjugation chemistry and intended downstream use (immunogen vs. assay antigen).
We provide commonly used carrier proteins and application-driven selection guidance to support antibody and assay success.
Dual-carrier strategies (e.g., KLH immunogen + BSA/OVA screening antigen) are recommended when specificity and reduced anti-carrier bias are priorities.
We perform peptide-to-carrier coupling under controlled conditions to support consistent loading, epitope exposure, and lot-to-lot reproducibility.
Our approach emphasizes practical performance outcomes: stronger immune response, cleaner screening, and reliable assay transfer.
QC is built into every project to confirm conjugation success, support downstream decisions, and reduce program risk for enterprise teams.
We support scale-up planning and documentation workflows for teams transitioning from discovery to preclinical and regulated programs.
Our manufacturing features:
To accelerate downstream success, we offer optional workflow support through qualified partners and internal guidance based on best practices.
Available support:
Carrier selection impacts immunogenicity, screening accuracy, and assay performance. Our carrier options and selection support are designed to help enterprise teams align immunization and screening strategies while minimizing background and improving specificity.
| Carrier Protein Type | Main Function | Common Examples | Typical Applications | Key Advantages |
|---|---|---|---|---|
| Immunization Carriers | Drive strong immune responses to peptide epitopes | KLH | Anti-peptide antibody generation, immunogen preparation | High immunogenicity; supports robust antibody titers |
| Screening & Assay Carriers | Provide consistent antigen presentation in immunoassays | BSA, OVA | ELISA coating, specificity screening, competitive assay formats | Stable and widely adopted; supports reproducible assay development |
| Human Matrix-Relevant Carriers | Support assay validation strategies in human samples | HSA | Assay development with reduced matrix interference risk | Improved relevance for clinical-like sample testing |
| Vaccine Research Carriers | Enable epitope-focused conjugate evaluation | CRM197 | Conjugate vaccine exploration, immunogenicity assessment | Well-characterized carrier in vaccine research contexts |
| Custom / Client-Supplied Proteins | Support proprietary platforms and internal standards | Provided per project need | Custom programs, platform-specific immunogens or controls | Tailored integration with enterprise workflows and requirements |
| Cleavable / Linker-Compatible Systems | Improve epitope accessibility for challenging targets | Spacer/linker-optimized conjugates | Sterically constrained epitopes, conformation-sensitive regions | Better exposure and functional antibody likelihood |
| Dual-Carrier Strategy | Separate immunization and screening antigens to improve hit quality | KLH + BSA/OVA | High-specificity antibody campaigns | Reduces anti-carrier bias and improves screening confidence |
Our Peptides–Carrier Protein Conjugation platform supports diverse peptide formats used in enterprise antibody discovery, immunoassay development, and vaccine research. We optimize conjugation chemistry and linker design to preserve epitope presentation and enable reproducible performance.
| Peptide Type | Full Name / Description | Typical Modifications | Applications | Conjugation Advantages |
|---|---|---|---|---|
| Linear Peptides | Standard epitope peptides designed from antigen regions for antibody generation | Cys addition, terminal handles, spacer insertion | Antibody production, epitope mapping, assay antigen preparation | Highly scalable with flexible coupling options |
| PTM Peptides | Post-translationally modified epitopes for modification-specific antibody development | Phospho (S/T/Y), acetyl, methyl, glyco-mimics | PTM-specific antibodies, pathway biology, biomarker validation | Improves immune focus on modification-dependent determinants |
| Cyclic / Constrained Peptides | Structure-stabilized epitopes that mimic native conformations | Disulfide, lactam cyclization, stapling | Conformation-specific antibodies, receptor-binding studies | Better structural mimicry for functional antibody outcomes |
| Long Peptides | Extended sequences for multi-epitope coverage or improved immunogenicity | Solubility tags, controlled coupling sites, spacers | Multi-epitope campaigns, vaccine epitope exploration | Broader immune engagement with adaptable conjugation strategies |
| Multivalent Constructs | Branched or repeated epitope designs to increase antigen density | Branched cores, repeat motifs, MAP-like constructs | High-avidity immunogens, diagnostic antigen engineering | Increased epitope density can enhance immune stimulation |
| Peptide Probes / Tags | Functional peptides for assay calibration and binding studies | Biotin, fluorescent dyes, PEG spacers | Assay controls, competitive formats, validation workflows | Enables standardized detection and improved reproducibility |
Enterprise-Grade Reproducibility
Defined process controls and loading targets support consistent results across lots, sites, and timelines.
Directional Coupling Options
Site-selective strategies improve epitope presentation and can reduce non-specific immune responses.
Carrier Portfolio for Immunogen & Assay
KLH for immunization; BSA/OVA/HSA for screening and assay development; CRM197 for vaccine research contexts.
Linker & Spacer Engineering
Spacer optimization helps prevent epitope masking and improves functional antibody likelihood.
Robust QC & Documentation
Traceable QC packages and CoA support enterprise decision-making and downstream program requirements.
Scalable Supply Options
From discovery lots to larger, GMP-aligned production options for preclinical and regulated workflows.
PTM & Challenging Epitope Support
Expertise with PTM peptides and difficult sequences improves success rates in specificity-driven campaigns.
Program-Fit Deliverables
Delivery formats and documentation designed for antibody teams, assay teams, and cross-functional enterprise stakeholders.
One-Stop Immunogen & Assay Antigen Solution
Integrated peptide synthesis, conjugation, purification, and QC accelerate timelines and reduce vendor complexity.
Our workflow is optimized for enterprise execution—combining technical rigor, traceability, and predictable timelines for immunogen and assay antigen delivery.
1
Consultation, Epitope Review & Program Design
2
Peptide Synthesis & Carrier Preparation
3
Controlled Conjugation & Optimization
4
Purification & QC Verification
5
Scale-Up, Documentation & Delivery
Peptides–Carrier Protein Conjugation enables enterprise programs to generate custom peptide immunogens and assay-ready peptide–protein conjugates with defined performance, documentation, and batch consistency. Below are six core application areas aligned with procurement, R&D, and quality requirements across biotech, pharma, and diagnostics organizations:
Ready to accelerate your custom peptide immunogen and peptide–carrier protein conjugation program? Partner with Creative Peptides for enterprise-ready delivery built on controlled coupling, defined loading targets, and traceable QC documentation. Whether you need KLH peptide conjugates for immunization, BSA/OVA peptide conjugates for ELISA screening, or specialized PTM peptide conjugates for specificity-driven campaigns, our experts provide scalable, professional solutions from design to delivery. Contact us today to discuss your project or request a technical consultation and quotation.
Peptides-carrier protein conjugation involves attaching small peptides to larger proteins to enhance their immunogenicity and facilitate immune responses. This method is crucial for generating effective immune responses in peptide-based vaccines and diagnostics.
Peptides are typically too small to elicit an immune response on their own. By conjugating them to larger carrier proteins like BSA or KLH, they can stimulate a stronger immune response, enabling applications in research and vaccine development.
Common carrier proteins include bovine serum albumin (BSA), ovalbumin (OVA), and keyhole limpet hemocyanin (KLH), each chosen based on their solubility, immunogenicity, and application needs in research or diagnostics.
KLH is a highly immunogenic protein, making it ideal for generating strong immune responses in immunoassays and vaccine development. Its unique structure provides excellent immunological properties compared to other carrier proteins like BSA and OVA.
The one-pot method combines the peptide and cross-linking reagent in a single step, followed by dialysis, while the two-step method uses separate reactions to attach the peptide to the carrier protein, allowing for more controlled conjugation.
By binding peptides to carrier proteins, researchers can track peptide distribution in tissues, providing valuable insights into disease progression and aiding in the identification of novel biomarkers for diagnostic purposes.
Yes, peptides conjugated with carrier proteins can be used in targeted therapeutic applications, such as in the development of peptide-based vaccines and diagnostic agents that specifically target disease-associated proteins or tissues.
